Key result
Low molecular weight heparin is the drug of choice for VTE during pregnancy, whereas warfarin is contraindicated in the first trimester and perinatal period due to teratogenicity and bleeding risks.
Why the study?
What is the safety profile and optimal management strategy for antithrombotic therapy during pregnancy?
What is the safety profile and optimal management strategy for antithrombotic therapy during pregnancy?
LMWH is preferred for VTE management in pregnancy due to its safety profile, whereas pregnant patients with mechanical heart valves require complex, staged anticoagulation management to balance maternal and fetal risks.
Answers are grounded in this paper and cite their sources.
Supports LMWH preference for pregnancy VTE; leaves open optimal valve strategies needing prospective validation.
A number of clinical conditions can require the use of antithrombotic drugs during pregnancy. These mainly include prevention of venous thromboembolism (VTE) and fetal complications in high-risk patients, treatment of VTE and prevention of arterial emboli in patients with mechanical heart valve prostheses. However, there are several problems when using antithrombotic drugs during pregnancy. Warfarin, as well as the other coumarin compounds, crosses the placenta and has the potential to cause both bleeding in the fetus and teratogenicity, therefore its use is not recommended during the first trimester and during the perinatal period. Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) do not cross the placenta and are safe for the fetus, but long-term treatment with UFH is problematic because of its inconvenient administration, the need to monitor anticoagulant activity and because of its potential side effects, such as heparin-induced thrombocytopenia and osteoporosis. LMWH is the drug of choice in the prevention and treatment of VTE during pregnancy because of its practical advantages over UFH and because of a lower risk of side effects. Patients with mechanical heart valve prostheses represent a major clinical challenge. Warfarin, the drug of choice in non-pregnant women, can be administered between the 12th and 36th week. Full-dose UFH is recommended in the first trimester and after week 36. The use of LMWH as an alternative to UFH is still a matter of debate, because inadequate data are available.
No takes yet. Share an insight, caveat, or question.
Ageno et al. (2004) conducted a review in Pregnancy requiring antithrombotic therapy. Antithrombotic therapy (Warfarin, UFH, LMWH) was evaluated. Low molecular weight heparin is the drug of choice for VTE during pregnancy, whereas warfarin is contraindicated in the first trimester and perinatal period due to teratogenicity and bleeding risks.
Synapse has enriched 10 related papers. Consider them for comparative context: